Serum sestrins: potential predictive molecule in human sarcopenia.
Asian Working group guidelines
Sarcopenia
Serum marker
Sestrin
Surface plasma resonance
Journal
Aging clinical and experimental research
ISSN: 1720-8319
Titre abrégé: Aging Clin Exp Res
Pays: Germany
ID NLM: 101132995
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
17
04
2020
accepted:
22
06
2020
pubmed:
1
7
2020
medline:
1
5
2021
entrez:
29
6
2020
Statut:
ppublish
Résumé
The aging trajectory from a state of robustness and good health proceeds from sarcopenia to frailty followed by disability and death due to decline in skeletal muscle mass and function. Sarcopenia is now formally recognized as a muscle disease with an ICD-10-MC diagnosis code. The autophagic response seems to be affected in the skeletal muscle during aging contributing to sarcopenia. Sestrins (Sesns) proteins play a critical role in autophagy induction under cellular stress conditions. The study aims to identify sarcopenia in older adults using Asian Working group guidelines (AWGS) to determine clinically relevant cut-off levels for diagnosis and their association with antioxidant protein Sesns. The study recruited 102 older adults attending Geriatric medicine OPD AIIMS, New Delhi, India. The level of serum Sesns were evaluated by Surface Plasmon Resonance (SPR) and validated by immunoblotting. Fifty older adults were diagnosed as sarcopenics according to AWGS. Sesn 1 (p = 0.0448) and Sesn 2 (p < 0.0001) levels were significantly reduced in sarcopenic compared to non-sarcopenic. ROC analysis showed a better cut-off of Sesn 2; 10.104 ng/µL with 92% sensitivity and 84% specificity. Even after adjusting the values with respect to confounding factors, Sesn levels remained significantly reduced in sarcopenics (p < 0.030). The level of Sesn 2 showed positive co-relation with the characteristics of sarcopenia. This study first time reported the concentration of serum sestrin in sarcopenic older adults. It can be concluded that sarcopenia can be diagnosed at the early stage by using the serum sestrin scale as one of the potential biomarker.
Sections du résumé
BACKGROUND
BACKGROUND
The aging trajectory from a state of robustness and good health proceeds from sarcopenia to frailty followed by disability and death due to decline in skeletal muscle mass and function. Sarcopenia is now formally recognized as a muscle disease with an ICD-10-MC diagnosis code. The autophagic response seems to be affected in the skeletal muscle during aging contributing to sarcopenia. Sestrins (Sesns) proteins play a critical role in autophagy induction under cellular stress conditions.
AIMS
OBJECTIVE
The study aims to identify sarcopenia in older adults using Asian Working group guidelines (AWGS) to determine clinically relevant cut-off levels for diagnosis and their association with antioxidant protein Sesns.
METHODS
METHODS
The study recruited 102 older adults attending Geriatric medicine OPD AIIMS, New Delhi, India. The level of serum Sesns were evaluated by Surface Plasmon Resonance (SPR) and validated by immunoblotting. Fifty older adults were diagnosed as sarcopenics according to AWGS.
RESULTS
RESULTS
Sesn 1 (p = 0.0448) and Sesn 2 (p < 0.0001) levels were significantly reduced in sarcopenic compared to non-sarcopenic. ROC analysis showed a better cut-off of Sesn 2; 10.104 ng/µL with 92% sensitivity and 84% specificity. Even after adjusting the values with respect to confounding factors, Sesn levels remained significantly reduced in sarcopenics (p < 0.030).
DISCUSSION
CONCLUSIONS
The level of Sesn 2 showed positive co-relation with the characteristics of sarcopenia. This study first time reported the concentration of serum sestrin in sarcopenic older adults.
CONCLUSION
CONCLUSIONS
It can be concluded that sarcopenia can be diagnosed at the early stage by using the serum sestrin scale as one of the potential biomarker.
Identifiants
pubmed: 32594460
doi: 10.1007/s40520-020-01642-9
pii: 10.1007/s40520-020-01642-9
doi:
Substances chimiques
Sestrins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1315-1324Références
Woo J, Arai H, Ng TP et al (2014) Ethnic and geographic variations in muscle mass, muscle strength and physical performance measures. European Geriatric Med 5:155–164
doi: 10.1016/j.eurger.2014.04.003
Cruz-Jentoft AJ, Baeyens JP, Bauer JM et al (2010) Sarcopenia: european consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing 39:412–423
doi: 10.1093/ageing/afq034
Chen L-K, Liu L-K, Woo J et al (2014) Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia. J Am Med Dir Assoc 15:95–101
doi: 10.1016/j.jamda.2013.11.025
ICD-10-CM Diagnosis Code M62.84: Sarcopenia [Internet]. [cited 2019 Nov 11]. https://www.icd10data.com/ICD10CM/Codes/M00-M99/M60-M63/M62-/M62.84
Singhal S, Singh S, Upadhyay AD et al (2019) Serum creatinine and cystatin C-based index can be a screening biomarker for sarcopenia in older population. Eur Geriatric Med 10:625–630
doi: 10.1007/s41999-019-00197-x
Kalinkovich A, Livshits G (2015) Sarcopenia-The search for emerging biomarkers. Ageing Res Rev 22:58–71
doi: 10.1016/j.arr.2015.05.001
Lee JH, Budanov AV, Park EJ et al (2010) Sestrin as a feedback inhibitor of TOR that prevents age-related pathologies. Science 327:1223–1228
doi: 10.1126/science.1182228
Lee JH, Budanov AV, Karin M (2013) Sestrins orchestrate cellular metabolism to attenuate aging. Cell Metab 18:792–801
doi: 10.1016/j.cmet.2013.08.018
Tyrovolas S, Koyanagi A, Olaya B et al (2016) Factors associated with skeletal muscle mass, sarcopenia, and sarcopenic obesity in older adults: a multi-continent study. J Cachexia Sarcopenia Muscle 7:312–321
doi: 10.1002/jcsm.12076
Rai N, Venugopalan G, Pradhan R et al (2018) Exploration of novel anti-oxidant protein sestrin in frailty syndrome in elderly. Aging Dis 9:220–227
doi: 10.14336/AD.2017.0423
Kumar R, Mohan N, Upadhyay AD et al (2014) Identification of serum sirtuins as novel noninvasive protein markers for frailty. Aging Cell 13:975–980
doi: 10.1111/acel.12260
Masiero E, Agatea L, Mammucari C et al (2009) Autophagy is required to maintain muscle mass. Cell Metab 10:507–515
doi: 10.1016/j.cmet.2009.10.008
Neel BA, Lin Y, Pessin JE (2013) Skeletal muscle autophagy: a new metabolic regulator. Trends Endocrinol Metab 24:635–645
doi: 10.1016/j.tem.2013.09.004
Iannuzzi-Sucich M, Prestwood KM, Kenny AM (2002) Prevalence of sarcopenia and predictors of skeletal muscle mass in healthy, older men and women. J Gerontol A Biol Sci Med Sci 57:M772–M777
doi: 10.1093/gerona/57.12.M772
Yanai H (2015) Nutrition for Sarcopenia. J Clin Med Res 7:926–931
doi: 10.14740/jocmr2361w
Landi F, Liperoti R, Russo A et al (2012) Sarcopenia as a risk factor for falls in elderly individuals: results from the ilSIRENTE study. Clin Nutr Edinb Scotl 31:652–658
doi: 10.1016/j.clnu.2012.02.007
Ida S, Kaneko R, Murata K (2018) SARC-F for screening of sarcopenia among older adults: a meta-analysis of screening test accuracy. J Am Med Dir Assoc 19:685–689
doi: 10.1016/j.jamda.2018.04.001
Yang YL, Loh KS, Liou BY et al (2013) Sesn1 is a positive regulator of lifespan in Caenorhabditis elegans. Exp Gerontol 48:371–379
doi: 10.1016/j.exger.2012.12.011